Silicon Labs has announced that its Series 3 Secure Vault security subsystem on the SiXG301 SoC has achieved PSA Level 4 ...

SRM University-AP, Amaravati, hosted a high-level strategic interaction with global leaders in clean energy to explore ...

SRM University-AP hosts global leaders in clean energy to collaborate on building a green hydrogen ecosystem in Andhra ...

Among patients with PsA, MetS was independently associated with a D2T phenotype, even when accounting for fibromyalgia and disease activity.

Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the ...

Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless, today announced that its Series 3 Secure Vault ...

The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.

Sun Pharma’s INSPIRE-1 and INSPIRE-2 studies met their primary endpoint at Week 24, with Ilumya 100 mg demonstrating superior efficacy over placebo in treating active psoriatic arthritis.